NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 4.2% – What’s Next?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares dropped 4.2% during mid-day trading on Friday . The stock traded as low as $0.4201 and last traded at $0.4204. 95,020 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 411,943 shares. The stock had previously closed at $0.4389.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Price Performance

The business’s fifty day moving average price is $0.58 and its 200-day moving average price is $0.73. The stock has a market capitalization of $15.88 million, a price-to-earnings ratio of -0.78 and a beta of 1.62.

Insider Transactions at NeuroSense Therapeutics

In related news, CEO Alon Ben-Noon purchased 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the acquisition, the chief financial officer directly owned 1,504,050 shares in the company, valued at approximately $1,203,240. This represents a 19.94% increase in their position. The SEC filing for this purchase provides additional information. 27.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics during the 2nd quarter valued at $56,160. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics in the 3rd quarter worth $26,000. Squarepoint Ops LLC raised its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the second quarter valued at about $54,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.